載入中
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
一般交易時段
US$99.285
+US$5.025 · +5.33%
盤中時間採用ET。市場資料可能有所延遲。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
日內區間
目前US$99.285
52週區間
目前US$99.285
盤中時間採用ET。市場資料可能有所延遲。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
日內區間
目前US$99.285
52週區間
目前US$99.285
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 2670.6萬 USD | 2594.7萬 USD | 1100.1萬 USD | 871.1萬 USD |
| 毛利 | — | −2670.6萬 USD | −2594.7萬 USD | −1100.1萬 USD | −871.1萬 USD |
| 研究與開發 | 1.82億 USD | 1.26億 USD | 2.06億 USD | 2.68億 USD | 2.17億 USD |
| 銷售、一般及管理費用 | 5201.5萬 USD | 3404.8萬 USD | 7102.3萬 USD | 6278.7萬 USD | 4100萬 USD |
| 營業費用 | 2.34億 USD | 1.6億 USD | 2.51億 USD | 3.3億 USD | 2.58億 USD |
| 利息收入 | 451.7萬 USD | 1114.8萬 USD | 1673.3萬 USD | 707.1萬 USD | 29.8萬 USD |
| 利息支出 | — | — | 1.3萬 USD | 1.8萬 USD | 2.2萬 USD |
| 折舊和攤銷 | 2632萬 USD | 2670.6萬 USD | 2594.7萬 USD | 1100.1萬 USD | 871.1萬 USD |
| 營業利益 | −2.34億 USD | −1.87億 USD | −2.77億 USD | −3.41億 USD | −2.67億 USD |
| 淨利 | −2.3億 USD | −1.76億 USD | −2.6億 USD | −3.34億 USD | −2.67億 USD |
公司資料更新於 2026年10月9日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
